Abstract
Background and aims An increasing body of observational studies has linked fructose intake to colorectal cancer (CRC). African Americans (AAs) are significantly more likely than European Americans to consume greater quantities of fructose and to develop right-side colon cancer. Yet, a mechanistic link between these two associations remains poorly defined. We aimed to identify differentially methylated regions (DMRs) associated with dietary fructose consumption measures obtained from food frequency questionnaires in a cohort of normal colon biopsies derived from AA men and women (n=79)
Methods DNA methylation data from this study was obtained using the Illumina Infinium MethylationEPIC kit and is housed under accession GSE151732. DMR analysis was carried out using DMRcate in right and matched left colon, separately. Secondary analysis of CRC tumors was carried out using data derived from TCGA-COAD, GSE101764 and GSE193535. Differential expression analysis was carried out on CRC tumors from TCGA-COAD using DESeq2.
Results We identified 4,263 right-side fructose-DMRs. In contrast, only 24 DMRs survived multiple testing corrections (FDR<0.05) in matched, left colon. To identify targets by which dietary fructose drives CRC risk, we overlaid these findings with data from three CRC tumor datasets. Remarkably, almost 50% of right-side fructose-DMRs overlapped regions associated with CRC in at least one of three datasets. TNXB and CDX2 ranked among the most significant fructose risk DMRs in right and left colon respectively that also displayed altered gene expression in CRC tumors.
Conclusions Our mechanistic data support the notion that fructose has a greater CRC-related effect in right than left AA colon, alluding to a potential role for fructose in contributing to racial disparities in CRC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by research grants from the National Cancer Institute Cancer Disparities SPORE Planning Grant (P20 CA233216), Case Comprehensive Cancer Center GI SPORE (P50 CA150964), National Cancer Institute (CA143237, CA204279), and a pilot grant from the University of Virginia Cancer Center (P30CA044579). Funders had no involvement in the study design, collection, analysis and interpretation of data or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Case Western Reserve University/UHCMC and the University of Virginia Institutional Review Boards (IRB-HSR-21219). This study followed Strengthening the Reporting of Observational Studies in Epidemiology guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Grant Support: The work was supported by research grants from the National Cancer Institute Cancer Disparities SPORE Planning Grant (P20 CA233216), Case Comprehensive Cancer Center GI SPORE (P50 CA150964), National Cancer Institute (CA143237, CA204279), and a pilot grant from the University of Virginia Cancer Center (P30CA044579). Funders had no involvement in the study design, collection, analysis and interpretation of data or writing of the report.
Disclosures: the authors have nothing to disclose. The authors have no conflicts of interest.
Transcript profiling: The data generated here are from our previously published, publicly available dataset: GSE151732.
Writing assistance: N/A.
Data Availability
The data generated already exist as publicly available data on Gene Expression Omnibus: GSE151732, GSE101764 and GSE193535 and through the GDC Portal: TCGA-COAD.
https://portal.gdc.cancer.gov/repository?facetTab=cases&filters=%7B%22content%22%3A%5B%7B%22content%22%3A%7B%22field%22%3A%22cases.project.project_id%22%2C%22value%22%3A%5B%22TCGA-COAD%22%5D%7D%2C%22op%22%3A%22in%22%7D%2C%7B%22content%22%3A%7B%22field%22%3A%22files.data_category%22%2C%22value%22%3A%5B%22Transcriptome%20Profiling%22%5D%7D%2C%22op%22%3A%22in%22%7D%5D%2C%22op%22%3A%22and%22%7D&searchTableTab=cases
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151732
Abbreviations
- AA
- African American
- BMI
- body mass index
- CAPI
- computer-assisted personal interview
- CRC
- colorectal cancer
- DEG
- differentially expressed gene
- DNAm
- DNA methylation
- EA
- European American
- FDR
- false-discovery rate
- FFQ
- food-frequency questionnaire
- HFCS
- high fructose corn syrup
- NAT
- normal-adjacent tissue
- SSB
- sugar sweetened beverage
- TCGA-COAD
- The Cancer Genome Atlas Colon Adenocarcinoma.
